A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)

Conditions

• Pulmonary Disease, Chronic Obstructive

Eligibility Criteria

Sex

ALL

Age

40 Years - 80 Years

Healthy Volunteers

Not accepted

Interventions

• GSK5784283 — DRUG
  GSK5784283 will be administered.
• Placebo — DRUG
  Placebo will be administered.
• Standard of care — DRUG
  Standard of care will be administered.

Study Details

The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.

Key Dates

First listed

Aug 21, 2026

Start date

Sep 11, 2026

Status verified

Sep 2026

Primary completion

Jul 20, 2029

Completion

Mar 15, 2030

Study Design

Enrollment

624 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Participants receiving GSK5784283 plus standard of care
• Placebo Comparator: Participants receiving matching placebo plus standard of care

Primary Outcome Measure

Annualized rate of moderate or severe COPD Exacerbations [ Time Frame: Up to Week 78 ]

Central Contacts

• US GSK Clinical Trials Call Center
  877-379-3718
  [email protected]
• EU GSK Clinical Trials Call Center
  +44 (0) 20 89904466
  [email protected]

Locations (4)

Find similar trials in Miami, FL

Related Studies

• A Study of the Effect of a Nurse Navigator Program on High Risk Patients
  Not Yet Recruiting · Mayo Clinic · Jacksonville, Florida
• Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
  PHASE3 · Recruiting · GlaxoSmithKline · Bakersfield, California
• Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
  PHASE3 · Recruiting · GlaxoSmithKline · Sheffield, Alabama
• eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
  PHASE3 · Recruiting · GlaxoSmithKline · Newport Beach, California